Loading...
NPI 1558717827 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Concord Life Sciences, LLC is a clinical medical laboratory provider located in Houston, Texas. This profile covers 137 Medicare and 133 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Concord Life Sciences, LLC |
| Address | 16840 Buccaneer Ln Ste 281 |
| City | Houston |
| State | TX |
| ZIP | 77058 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 5, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $9.6M |
| Medicaid | $1.3M |
CONCORD LIFE SCIENCES, LLC is a clinical diagnostic laboratory with a heavy emphasis on amplified nucleic acid probe testing; its top Medicare codes are 87798, 87801 and a third set that together account for 61.4% of Medicare revenue, indicating the operation is structured around high-volume molecular infectious-agent testing rather than routine anatomic pathology or high-dollar specialty procedures. The presence of many amplified probe codes (87798, 87801, 87651, 87653, 87640, 87641, 87500) across the top lists reinforces that the business is organized as a molecular infectious-disease testing center servicing broad specimen volumes. The lab also bills standard clinical chemistry and hematology panels (80048, 80053, 80061, 85025) reflecting a complementary general lab service line alongside its molecular testing core.
Medicare revenue is the dominant payer stream for this provider: lifetime Medicare revenue is $9.6M versus lifetime Medicaid revenue of $1.3M, making Medicare the primary commercial scale driver for the entity. On Medicare specifically, the top three codes by revenue account for 61.4% of the provider's Medicare revenue, signaling substantial revenue concentration in a few molecular test codes rather than a broad, evenly distributed code mix. For Medicaid the top three codes account for 54.0% of Medicaid revenue, showing a similar, though slightly less concentrated, reliance on a small set of testing services.
The provider is a national high-volume performer on several specific molecular codes: for Medicare, 87798 generates $3.6M (39.2% of the provider’s Medicare revenue) and 87801 generates $1.7M (18.3%); both codes are labeled as outliers in national ranking (87798 ranks #12 of 1319 providers nationally at the 99th percentile and 87801 ranks #4 of 561 providers nationally at the 99th percentile). These rankings indicate CONCORD is a major national contributor for broad amplified-probe infectious-agent testing and operates well above typical national volume for those services. Other amplified-probe codes such as 87651, 87653, 87640 and 87641 also sit at high national percentiles, reinforcing a pattern of concentrated, above-typical molecular testing volume.
On Medicaid within Texas, CONCORD shows elevated standing for many of the same molecular codes but at the state level: 87798 is $375.9K (29.6% of Medicaid revenue) and ranks #11 of 243 in-state (96th percentile), while 87801 is $191.7K (15.1%) and ranks #6 of 109 in-state (95th percentile). Several other molecular codes are top statewide performers (e.g., 87500 ranks #3 of 103 in-state as an extreme outlier), indicating the lab is also a significant state-level provider of nucleic-acid-based infectious disease and resistance testing for Medicaid patients. However, Medicaid volumes and payments are much smaller in absolute dollars versus Medicare, reflecting a payer mix skewed to Medicare.
The provider’s competitive footprint is mixed by payer: nationally for Medicare CONCORD is a dominant or extreme outlier on multiple molecular codes (multiple #-rankings in the top percentiles such as #4, #8, #11, #12), which positions it as a large national-volume lab for those specific tests. In contrast, for Medicaid the firm is a strong in-state performer on many of the same codes (several top-5 or top-15 state ranks and multiple 95th–98th percentile positions), indicating regional leadership within Texas but with overall Medicaid revenue much smaller than its Medicare business. For commodity lab services (CBC 85025, BMP 80048, CMP 80053, vitamin D 82306, TSH 84443), the provider often ranks high in volume percentiles but these codes contribute modestly to total revenue, suggesting molecular testing is the primary differentiator in competitive standing.
Revenue concentration and code-level outlier status imply operational scale and specialization risk: the fact that the top three Medicare codes account for 61.4% of Medicare revenue and top three Medicaid codes account for 54.0% of Medicaid revenue means the business depends heavily on a small set of amplified-probe molecular tests. Several of those codes are explicitly called out as "extreme outlier" or "notably above typical," which signals the provider runs very high throughput for those assays. That concentration could be advantageous for negotiating network placement or pricing for those services but also creates exposure if testing demand, reimbursement, or coding environment changes for those specific assays.
The NPI enumeration date shows CONCORD LIFE SCIENCES, LLC has been registered since 2016-05-05 (~10 years ago), indicating roughly a decade of billing history and suggesting established operations and payer relationships. This tenure, combined with repeated high national/state percentiles across molecular codes, supports the interpretation that the laboratory has scaled its molecular testing volume over multiple years rather than being a short-term entrant. Analysts should consider this longevity when evaluating contracting leverage and historical volume trends.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
137 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 105,470 | $30 | $3.6M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 29,360 | $60 | $1.7M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 10,340 | $30 | $351.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 9,750 | $30 | $331.6K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 9,750 | $30 | $331.6K |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 31,920 | $10 | $319.2K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 9,370 | $30 | $318.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,080 | $240 | $261.1K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 256,270 | $1 | $256.3K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6,110 | $30 | $207.9K |
Showing 1–10 of 137
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 137 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
137 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87637 | 12 | 70 | 40 | $140 | $404.2K |
| 87798 | 6 | 300 | 790 | $30 | $265.1K |
| 87801 | 2 | 120 | 170 | $70 | $86.5K |
| G0483 | 13 | 170 | 150 | $240 | $84.9K |
| P9603 | 2 | 30 | 26,220 | $1 | $73.2K |
| 87481 | 12 | 270 | 150 | $30 | $68.8K |
| G0471 | 1 | 20 | 1,800 | $10 | $66.5K |
| U0003 | 41 | 60 | 100 | $70 | $64.7K |
| G0482 | 52 | 200 | 150 | $190 | $54K |
| G0480 | 13 | 140 | 80 | $110 | $38.8K |
Showing 1–10 of 137
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
133 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 16,340 | $20 | $375.9K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 15,970 | $10 | $191.7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,960 | $30 | $118.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 15,700 | $10 | $78.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 6,850 | $10 | $75.3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,040 | $30 | $57K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 51,730 | $1 | $51.7K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 15,690 | $1 | $47.1K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 10,830 | $1 | $32.5K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 15,700 | $1 | $31.4K |
Showing 1–10 of 133
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
133 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 85 | 340 | 400 | $50 | $553.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 99 | 120 | 340 | $120 | $422K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 57 | 150 | 170 | $30 | $302.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 11 | 240 | 420 | $30 | $296.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 114 | 140 | 180 | $60 | $215.9K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 6 | 110 | 360 | $40 | $174.9K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 14 | 100 | 650 | $50 | $161.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 88 | 260 | 640 | $20 | $137.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 27 | 70 | 200 | $50 | $124.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 26 | 350 | 510 | $30 | $114.1K |
Showing 1–10 of 133
Other providers in the same ZIP code as Concord Life Sciences, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Gulf Coast Community Health Services, Inc | TX | Home Health Agency | $0 | $45M |
| Joezer Lugo Ranal | TX | Physical Medicine & Rehabilitation Physician | $1M | $0 |
| Orbis Surgery Center LLC | TX | Ambulatory Surgical Clinic/Center | $854.7K | $1.1K |
| Daniel O'neill | TX | Orthopaedic Surgery Physician | $309.7K | $0 |
| Bill Chang | TX | Vascular Surgery Physician | $291.9K | $0 |
| Matthew Higgs | TX | Sports Medicine (Family Medicine) Physician | $204.2K | $0 |
| Joseph Naoum | TX | Vascular Surgery Physician | $169.8K | $0 |
| Marston Holt | TX | Orthopaedic Surgery Physician | $166.1K | $0 |
| Dennis Zgaljardic | TX | Clinical Neuropsychologist | $124.8K | $0 |
| Bingzhong Chen | TX | Neurology Physician | $96.1K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.